nejm retatrutide 2024 Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 GLP-1 Medications for Weight Loss:

A provider may recommend slower dose escalation to minimize glycosuria exposure during the titration phase, or may defer treatment pending fungal assessment if baseline risk is very high

Therefore, it will be necessary for future work to examine GLP-1 users experiences of stigma in everyday life to quantify the frequency and intensity with which it is experienced

Endocrinology 2004, 145, 26532659

Apesar dos inmeros benefcios, o incio do tratamento com agonistas de GLP-1 pode estar associado a sintomas gastrointestinais

Many patients start with Semaglutide and later transition to Tirzepatide under physician guidance

Suraj Malhan, DO, headache and facial pain neurologist at RWJBarnabas Health, Monmouth Medical Center